EUCTR2007-004347-30-HU进行中（未招募）1 期
A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine co-administered with GlaxoSmithKline Biologicals’ inactivated hepatitis A and hepatitis B vaccine adsorbed (Twinrix® Paediatric) in healthy female subjects aged 9–15 years. - HPV-029 PRI
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 814
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •All subjects must satisfy the following criteria at study entry:
- •Subjects who the investigator believes that they and/or their legally acceptable representatives (LARs) can and will comply with the requirements of the protocol should be enrolled in the study.
- •A female between, and including, 9 and 15 years of age at the time of the first vaccination.
- •Written informed consent obtained from subject's LAR and written informed assent obtained from the subject.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
- •Subjects must not be pregnant. Absence of pregnancy should be verified with a urine pregnancy test.
- •Subjects must be of non-childbearing potential, i.e., have a current tubal ligation, hysterectomy, ovariectomy or be pre-menarcheal, or if the subject is of childbearing potential, she must be abstinent or use adequate contraception for 30 days prior to vaccination and must agree to continue such precautions for two months after completion of the vaccination series. Subjects who reach menarche (begin menstruating) during the study, and therefore become of childbearing potential, must agree to follow the same precautions.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The following criteria should be checked at the time of study entry. If any apply, the subject must not be included in the study:
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- •Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
- •Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after each dose of vaccine(s).
- •A subject planning to become pregnant, likely to become pregnant (as determined by the investigator) or planning to discontinue contraceptive precautions during the study period and up to two months after the last vaccine dose.
- •Pregnant or breastfeeding women.
- •Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period.
- •Previous administration of MPL or AS04 adjuvant.
- •Previous vaccination against hepatitis A or B or planned administration of any hepatitis A or B vaccine other than that foreseen by the study protocol during the study period.
- •History of hepatitis A or B infection.
- •Known exposure to hepatitis A or B within the previous 6 weeks.
- •Known acute or chronic, clinically significant neurologic, hepatic or renal functional abnormality, as determined by previous physical examination or laboratory tests.
- •Cancer or autoimmune disease under treatment.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccines (e.g. aluminium, MPL).
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •Acute disease at the time of enrolment.
- •Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period. Enrolment will be postponed until the subject is outside the specified window.
研究者
相似试验
进行中（未招募）
不适用
A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine co-administered with GlaxoSmithKline Biologicals’ inactivated hepatitis A and hepatitis B vaccine adsorbed (Twinrix® Paediatric) in healthy female subjects aged 9–15 years. - HPV-029 PRIFor active immunization of females from the age of 10 years onwards for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (ASC-US), cervical intraepithelial neoplasia (CIN) and pre-cancerous lesions (CIN 2/3) caused by oncogenic human papillomavirus (HPV) types 16 and 18.EUCTR2007-004347-30-SEGlaxoSmithKline Biologicals810
进行中（未招募）
1 期
A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 AS04 vaccine co-administered with GlaxoSmithKline Biologicals’ combined reduced-antigen diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Boostrix® Polio) in healthy female subjects aged 10–18 years. - HPV-042In female subjects from 10 years of age onwards for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities including ASC-US, cervical intraepithelial neoplasia (CIN) and pre-cancerous lesions caused by oncogenic human papillomaviruses (HPV).EUCTR2006-003807-38-FRGlaxoSmithKline Biologicals751
进行中（未招募）
1 期
A multicentre study to evaluate the immunogenicity and safety of GSK Biologicals? HPV vaccine (580299) co-administered with Boostrix Polio in healthy female subjects aged 10?18 years.In female subjects from 10 years of age onwards for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities including ASC-US, cervical intraepithelial neoplasia (CIN) and pre-cancerous lesions caused by oncogenic human papillomaviruses (HPV).MedDRA version: 14.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2006-003807-38-ESGlaxoSmithKline S.A.751
进行中（未招募）
1 期
A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix™) co-administrated with GlaxoSmithKline Biologicals’ Hepatitis B vaccine (Engerix-B™) in healthy female subjects aged 9 - 15 years. - HPV-030 PRIFor the prevention of high grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18EUCTR2007-007783-14-NLGlaxoSmithKline Biologicals756
进行中（未招募）
不适用
A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix™) co-administrated with GlaxoSmithKline Biologicals’ Hepatitis B vaccine (Engerix-B™) in healthy female subjects aged 9 - 15 years. - HPV-030 PRIFor the prevention of high grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18EUCTR2007-007783-14-SEGlaxoSmithKline Biologicals756